At a Glance
Talis Capital and Speedinvest led a $5.5M seed round for Seqera Labs, a life sciences data orchestration and workflow software company. The new funds will be used to advance the company’s technology and expand its presence in North America.
Seqera Labs, a data orchestration and workflow software provider for life sciences, has announced that it has raised $5.5 million in a seed funding round co-led by Talis Capital and Speedinvest. The other participant was BoxOne Ventures. A grant from the Chan Zuckerberg Initiative, launched by Mark Zuckerberg and Dr. Priscilla Chan, is also a part of the funding.
The new funds will be used to improve the company’s technology and expand its footprint in North America.
Seqera Labs was formed in 2018 by the creators of Nextflow, an open-source workflow, and data orchestration software, as a spin-off from the Centre for Genomic Regulation (CRG). Seqera Labs continues developing the Nextflow platform to help organizations expand their analysis across diverse infrastructure, which is one of the most difficult problems in the life sciences industry.
The company’s core technology facilitates and simplifies complicated multi-cloud deployments of data analysis pipelines, monitors and optimizes drug research and development costs, speeds up clinical diagnostics, and enables data-driven life sciences solutions.
According to Seqera Labs’ press release, during the pandemic in 2020, the program acquired even more traction as it was used in global SARS-CoV-2 sequencing efforts. Using Nextflow’s platform, sequencing centres and specialists collaborated to establish processes for analyzing COVID-19 samples, resulting in the detection and ongoing surveillance of variants such as Alpha and Delta. The company is also enabling advancements in tailored medicine, particularly in personalized oncology, which is expected to grow rapidly in the future years. Gritstone Bio is Seqera’s customer who uses Nextflow for machine learning workloads in their customized cancer solutions across research and production sectors.
The last decade has seen an intensified demand for tools that can manage and process complex data. From personalized immunogenic vaccines to new diagnostics, our customers are performing work paramount to our global health. Joining forces with Speedinvest and Talis Capital provides us with an unparalleled opportunity to grow our reach and serve these customers better. This partnership is centered on a shared belief in a future transformed by data science research, applications and products. We welcome them into the Nextflow community and are excited at the prospect of building a better world together.Evan Floden, CEO and co-founder at Seqera Labs
While the company is now focusing on the medical sciences industry, businesses may use the software in any computationally intensive data pipeline application, such as machine learning and AI, manufacturing, and financial services.
Advancements in machine learning, and the proliferation of volumes and types of data, are leading to increasingly more applications of computer science in life sciences and biology. While this is incredibly exciting from a humanity perspective, it’s also skyrocketing the cost of experiments to sometimes millions of dollars per project as they become computer-heavy and complex to run. Nextflow is already a ubiquitous solution in this space, and Seqera is driving those capabilities at an enterprise level – and in doing so, is bringing the entire life sciences industry into the modern age. We’re thrilled to be a part of Seqera’s journey.Kirill Tasilov, principal at Talis Capital
With the explosion of biological data from cheap, commercial DNA sequencing, there is a pressing need to analyze increasingly growing and complex quantities of data. Seqera’s open and cloud-first framework provides an advanced tooling kit allowing organizations to scale complex deployments of data analysis and enable data-driven life sciences solutions. We couldn’t be more excited to partner with the team and support them in accelerating innovation in the healthcare industry.Arnaud Bakker, principal at Speedinvest
Five of the world’s major pharmaceutical corporations are among Seqera’s customers. Seqera sees strong, record demand for its commercial and open source services as life sciences data volumes and related analyses in pharmaceuticals, biotech, and life sciences grow dramatically. The commercial cloud solution has handled its five billionth task, and the Nextflow runtime has been downloaded over 2 million times.